What's Happening?
Tevogen.AI, a division of Tevogen Bio Holdings Inc., has announced significant advancements in its PredicTcell beta model, which is designed to improve the precision of drug discovery. The company has expanded its proprietary peptide database to over 655
million sequences, enhancing the model's ability to predict biological targets that are likely to succeed in clinical trials. Recent beta testing showed improvements in recall from 87% to 92% and precision from 40% to 48%, indicating fewer incorrect predictions and more accurate target identification. This development is part of Tevogen's broader strategy to reduce the time and cost associated with drug development by improving target prediction before clinical testing.
Why It's Important?
The advancements in Tevogen.AI's PredicTcell beta model are crucial for the pharmaceutical industry, as they promise to streamline the drug development process. By improving the accuracy of target predictions, Tevogen aims to reduce the reliance on trial-and-error methods, which are costly and time-consuming. This could lead to faster market entry for new drugs, lower development costs, and increased clinical success rates. The improvements also have the potential to extend the value of patent-protected products, offering significant economic benefits to pharmaceutical companies and potentially leading to more affordable treatments for patients.
What's Next?
Tevogen plans to explore partnerships with pharmaceutical companies to advance select peptide candidates for production and development. As the predictive accuracy of the PredicTcell model continues to improve, these partnerships could facilitate the development of targeted therapies for cancers and infectious diseases. The company is also focused on leveraging its AI platform to predict the proteome for any given protein-HLA combination, which could further enhance the efficiency and success of drug discovery efforts.
